Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers

Acta Haematol. 1994;92(1):1-7. doi: 10.1159/000204128.


Serum levels of various immunochemical markers of clinical interest, as interleukin-6 (IL-6), C-reactive protein (CRP) and beta 2-microglobulin (beta 2M), were measured in sera from 98 subjects affected with monoclonal gammopathy of undetermined significance (MGUS; 80% of which bearing cancer too) and from 39 patients with multiple myeloma (MM). In addition, the ratio between serum IgG/IgA amounts (GAR) was also calculated in monoclonal gammopathies of IgG type. Consistent with our previous investigations, we found that tumor presence significantly influenced the serum levels of the various markers (except GAR) in MGUS patients; in fact, only when comparing MGUS without tumor and MM patients, was a clear difference observed for all markers considered. The data presented discourage the use of IL-6, CRP and beta 2M as discriminant indices between MGUS and MM patients, unless a careful selection of MGUS subjects is performed. Further investigations on these potential markers are therefore needed for a more rational clinical application.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Biomarkers, Tumor / blood*
  • C-Reactive Protein / analysis
  • Female
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin G / blood
  • Interleukin-6 / blood*
  • Male
  • Middle Aged
  • Multiple Myeloma / blood*
  • Paraproteinemias / blood*
  • Statistics as Topic
  • beta 2-Microglobulin / analysis


  • Biomarkers
  • Biomarkers, Tumor
  • Immunoglobulin A
  • Immunoglobulin G
  • Interleukin-6
  • beta 2-Microglobulin
  • C-Reactive Protein